Archived Newsletters
-
04.10.24 -- From Ally To Adversary: BIO's Swift Rebuke Of WuXi
4/10/2024
04/10/24 Outsourced Pharma Newsletter
-
04.09.24 -- From Ally To Adversary: BIO's Swift Rebuke Of WuXi
4/9/2024
04/09/24 Outsourced Pharma Newsletter
-
04.08.24 -- Shocking! Biotech Facilities Don't Maintain Themselves
4/8/2024
04/08/24 Outsourced Pharma Newsletter
- Best of March: Top 5 Insights in Outsourced Drug Development and Manufacturing 4/5/2024
-
04.05.24 -- New Episodes: Allogeneic Cell Therapy Toxicities (and how to reduce them); Biotech and The Innovator's Dilemma.
4/5/2024
04/05/24 Outsourced Pharma Newsletter
-
04.05.24 -- Process Development: Stuck In The Middle With You
4/5/2024
04/05/24 Outsourced Pharma Newsletter
-
04.04.24 -- Beyond (And Better Than) mRNA: T Cell Vaccines
4/4/2024
04/04/24 Outsourced Pharma Newsletter
-
04.03.24 -- Streamline Your Outsourcing Journey & Discover Top CDMOs
4/3/2024
04/03/24
-
04.03.24 -- How Pharma 4.0 Can Unlock The Full Potential Of External Manufacturing
4/3/2024
04/03/24 Outsourced Pharma Newsletter
-
04.02.24 -- 2024's Market Outlook For Cell & Gene Therapies
4/2/2024
04/02/24 Outsourced Pharma Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more